Neptune Technologies & Bioressources
Basic Shares: 48.2 million
Fully diluted: 53.9 million
Neptune announced its quarterly results for the first quarter ended May 31, 2012. The company reported revenue of $6.153 million, which represents an increase of 44% over the same period last year. According to management, this is a result of aggressive penetration of its nutraceutical business into the US, Canada and Australia and an “unprecedented” rise in gross margin of 59%.
Neptune is a rare company in that one business segment is able to almost completely fund the research and development of the other non – revenue generating segments of the business.
Its two subsidiaries Acasti Pharma (Cardiovascular) and NeuroBioPharm (Neurological) are represented below.
To view today’s news release, please click here......